NCT05731232 (ViIBS) is a NA clinical trial of Vivatlac Synbiotikum in Irritable Bowel Syndrome, sponsored by The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz.

What drugs are being tested in NCT05731232?

Interventions in NCT05731232: Vivatlac Synbiotikum.

What condition does NCT05731232 study?

NCT05731232 studies Irritable Bowel Syndrome.

Is NCT05731232 still recruiting?

NCT05731232 is currently completed. Last updated 5 April 2024.

Last reviewed 2024-04-05 · How we verify

NCT05731232: ViIBS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Vivatlac Synbiotikum in Patients With Irritable Bowel Syndrome

Completed NA Last updated 5 April 2024

What this trial tests

NA trial testing Vivatlac Synbiotikum in Irritable Bowel Syndrome in 201 participants. Completed in 30 November 2023.

Timeline

1 February 2023

Primary endpoint
30 November 2023

30 November 2023

Quick facts

Lead sponsor	The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	201
Start date	1 February 2023
Primary completion	30 November 2023
Estimated completion	30 November 2023
Sites	2 locations across Poland

Drugs / interventions tested

Vivatlac Synbiotikum

Conditions studied

Irritable Bowel Syndrome — all drugs for Irritable Bowel Syndrome →

Sponsor

The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz

Who can join

Adults 18 to 65, any sex, with Irritable Bowel Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multi-centre, randomized, double-blind, placebo-controlled trial investigating the effects of a nine-strain synbiotic (Vivatlac Synbiotikum) in IBS patients.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Effectiveness of a Balanced Nine-Strain Synbiotic in Primary-Care Irritable Bowel Syndrome Patients-A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial.
Sommermeyer H, Chmielowiec K, Bernatek M, Olszewski P, et al · · 2024 · cited 7× · PMID 38794741 · DOI 10.3390/nu16101503
Synbiotics as Treatment for Irritable Bowel Syndrome: A Review.
Sommermeyer H, Piątek J. · · 2024 · cited 4× · PMID 39065261 · DOI 10.3390/microorganisms12071493
Targeting Irritable Bowel Syndrome Through Diet and Mechanism-Based Therapies: A Pathophysiological Approach.
Aggeletopoulou I, Karaivazoglou K, Kalafateli M, Triantos C. · · 2025 · cited 1× · PMID 41305645 · DOI 10.3390/nu17223595
Irritable bowel syndrome clinical trials: getting the IBS Severity Scoring System responder rate right
Sommermeyer H, Chmielowiec K, Wojtyła-Buciora P, Bernatek M, et al · · 2025

Verify or expand the search:

Other recruiting trials for Irritable Bowel Syndrome

Currently open trials in the same condition.

NCT07235228 — Effects of Vivatlac Synbiotic on Gut Micribiota of IBS Patients · NA · recruiting
NCT07421011 — Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 · Phase 1 · recruiting
NCT07360938 — Drug Interaction Potential of Pro-Inflammatory Conditions · recruiting
NCT06788444 — Efficacy of Esketamine for Patients With Irritable Bowel Syndrome · NA · recruiting
NCT07484412 — Efficacy and Safety of Encapsulated Bifidobacterium Longum BBH016 in Subjects With Lower Gastrointestinal Symptoms · NA · active not recruiting

Other The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz trials

Trials by the same sponsor.

NCT07235228 — Effects of Vivatlac Synbiotic on Gut Micribiota of IBS Patients · NA · recruiting
NCT07304622 — Impact of Various Therapeutic Methods on Gait Quality, Physical and Mental Fitness of Postmenopausal Women. · NA · completed
NCT04487834 — Effects of Vivatlac Baby on Crying Behavior of Colicky Babies · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05731232 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz
Last refreshed: 5 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05731232.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing